Preventing the Next Fertility Clinic Scandal
By Jesse Reynolds,
Bioethics Forum
| 03. 13. 2009
Given the U.S. fertility industry's longstanding resistance to effective oversight, the field's two recent controversies - first octuplets, then an offer of embryo screening for cosmetic traits - shouldn't really come as a surprise. What was remarkable about the reaction they evoked from knowledgeable observers, in fact, was the chorus of agreement that it's time to leave the "Wild West" days of assisted reproduction behind.
The octuplets story turned many of us into reluctant voyeurs, fascinated by the daily dribble of details. Fortunately, at least some of the media attention soon turned away from the unsettling details about the babies' mother and focused instead on the fertility doctor involved. We soon learned that Michael Kamrava had not only transferred six embryos - two of which divided into twins - into the octuplets' mother, but had also recently put seven embryos into another woman who wanted only one child, leaving her pregnant with quadruplets.
The industry that had tolerated such irresponsible medical conduct also came under much-needed scrutiny. Many people were surprised to learn that the multibillion dollar American fertility industry...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...